Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001010421 | SCV001170620 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2017-12-04 | criteria provided, single submitter | clinical testing | The c.1225+2T>C intronic variant results from a T to C substitution two nucleotides after coding exon 10 in the MRE11A gene. This nucleotide position is highly conserved in available vertebrate species. Using two different splice site prediction tools, this alteration is predicted by BDGP to abolish the native splice donor site, but is predicted to weaken (but not abolish) the efficiency of the native splice donor site by ESEfinder; however, direct evidence is unavailable. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. |
Revvity Omics, |
RCV001784556 | SCV002017547 | pathogenic | Ataxia-telangiectasia-like disorder 1 | 2019-05-16 | criteria provided, single submitter | clinical testing |